Premium
Combinations of monoclonal antibodies can distinguish primary lung tumors from metastatic lung tumors sampled by fine needle aspiration biopsy
Author(s) -
Mottolese Marcella,
Venturo Irene,
Rinaldi Massimo,
Campioni Norberto,
Aluffi Antonello,
Curcio Corrado Gallo,
Donnorso Raffaele Perrone,
Natali Pier Giorgio
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19891215)64:12<2493::aid-cncr2820641215>3.0.co;2-s
Subject(s) - medicine , fine needle aspiration , lung , pathology , biopsy , lung cancer , radiology , monoclonal antibody , immunocytochemistry , cytopathology , cytology , lesion , primary tumor , metastasis , cancer , antibody , immunology
Transthoracic fine needle aspiration (FNA) biopsies performed under computed tomography (CT) scan (CT‐FNA) have greatly improved the cytodiagnosis of lung tumors. However, the distinction between a primary lesion and a metastatic lesion still may be difficult on the basis of morphologic criteria. To evaluate whether a selected panel of monoclonal antibodies (MoAb) to tumor‐associated antigens (TAA) can improve the diagnostic potential of FNA, we have immunocytochemically analyzed 122 pulmonary CT‐FNA. Whereas conventional cytology was capable of recognizing only the neoplastic nature of the lesions, the immunocytochemical diagnosis could identify the primary or metastatic nature of the pulmonary masses in 92.5% of the cases. The immunocytochemical findings were confirmed by clinical—histopathologic data. The current results demonstrate that the use of immunocytochemical methods can significantly improve the diagnostic accuracy of conventional cytology of lung masses. Cancer 64:2493–2500, 1989.